CG
ELDN icon

Colony Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Colony Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-12
Closed -$17K – 359
2015
Q4 		$17K Hold
12
– – ﹤0.01% 566
2015
Q3 		$21K Buy
+12
New +$24.7K ﹤0.01% 538

Other funds holding ELDN

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Colony Group's ELDN Position: Q1 2016 in Review

Colony Group sold out of Eledon Pharmaceuticals (ELDN) in Q1 2016, closing a stake of 12 shares — an estimated $17K sold.

Colony Group first reported a position in ELDN in Q3 2015 and held it in 2 quarters. The position peaked at $21K in Q3 2015. 49 funds tracked by Wall St. Rank hold ELDN as of Q1 2016.

  • Colony Group reported no remaining Eledon Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Colony Group sold 12 Eledon Pharmaceuticals shares in Q1 2016, an estimated $17K.
  • Colony Group first reported a position in Eledon Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Colony Group's Eledon Pharmaceuticals position peaked at $21K in Q3 2015.
  • 49 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2016.

Based on Colony Group's 13F filing for Q1 2016, filed 16 May 2016.